BRAF V600E

CI-VAR-00004575Explore in graph →NP_004324.2:p.Val600GluNM_004333.4:c.1799T>AClinVar 13961 CIViC 12 rs113488022

Curated evidence

Evidence by cancer (259 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–50 of 259 evidence items across 21 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Childhood Low Grade Glioma2
BRAF V600E	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID7191 Using Sanger sequencing, BRAFV600E mutations were identified in 21 of 285 patients with PLGGs (7.4%). This mutation was enriched in hemispheric tumors (p<0.007) and was associated with shorter progres… (full text at CIViC) PMID 29948154 · Yang et al., 2018 · Open in CIViC	civic
BRAF V600E OR KIAA1549::BRAF Fusion	Tovorafenib	Predictive	A	Supports Sensitivity Response	5	accepted	EID12016 In this ongoing phase 2 trial (FIREFLY-1), 76 patients, aged 6 months to 25 years, with pediatric low-grade glioma harbouring BRAF alterations (BRAF fusions or BRAF V600E mutations) were treated with … (full text at CIViC) PMID 37978284 · Kilburn et al., 2024 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Childhood Pilocytic Astrocytoma2
BRAF V600E	Selumetinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID7485 In a phase 2 trial, patients with pediatric low-grade glioma after at least one standard therapy were treated with MEK1/2 inhibitor selumetinib. In stratum 1, nine patients with WHO grade I pilocytic… (full text at CIViC) PMID 31151904 · Fangusaro et al., 2019 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	3	accepted	EID3777 In a case report, a 28 month old patient with a cervicomedullary low grade glioma compatible with pilocytic astrocytoma which was resected had a second lesion consistent with a ganglioglioma 3 years l… (full text at CIViC) PMID 25524464 · del Bufalo et al., 2014 · Open in CIViC	civic

Cholangiocarcinoma3
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	B	Supports Sensitivity Response	3	submitted	EID7453 In NCI-MATCH trial, patients with advanced solid tumors, lymphoma or multiple myeloma harboring BRAF V600E mutation were treated with dabrafenib and trametinib. Patients with melanoma, thyroid carcino… (full text at CIViC) Open in CIViC	civic
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	C	Supports Sensitivity Response	3	accepted	EID5902 Chemotherapy-refractory, metastatic cholangiocarcinoma with CNS involvement and a BRAF V600E mutation had a partial response at 8 weeks to dabrafenib and trametinib combination with complete radiologi… (full text at CIViC) PMID 28480077 · Kocsis et al., 2017 · Open in CIViC	civic
BRAF V600E	Irinotecan + Panitumumab + VemurafenibCombination	Predictive	C	Supports Sensitivity Response	3	accepted	EID5906 A 31 year old patient with metastatic cholangiocarcinoma with BRAF V600E was treated with vemurafenib, panitumumab and irinotecan triplet therapy. By 2 months, 50% reduction of tumor volume was noted,… (full text at CIViC) PMID 26687137 · Silkin et al., 2016 · Open in CIViC	civic

Clear Cell Sarcoma of Soft Tissue1
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3779 In a case report, a clear cell sarcoma patient harboring BRAF V600E mutation with distant metastases was associated with a complete response to vemurafenib monotherapy at 8 weeks of treatment. Prior t… (full text at CIViC) PMID 26286452 · Protsenko et al., 2015 · Open in CIViC	civic

Colon Carcinoma1
BRAF V600E AND MSI Low	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID12072 5577 colon carcinoma tumors were evaluated for BRAF, KRAS, and mismatch repair status. From those successfully evaluated, 201 had microsatellite instability (MSI or MSI-H) and BRAF V600E, 72 had MSI a… (full text at CIViC) PMID 28040692 · Taieb et al., 2017 · Open in CIViC	civic

Colorectal Adenocarcinoma3
BRAF V600E	Cetuximab	Predictive	D	Does Not Support Sensitivity Response	3	rejected	EID12446 Cell growth of several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Cell lines with activating BRAF mutations were insensitive, … (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic
BRAF V600E AND MSI High	(prognostic)	Prognostic	B	Supports Poor Outcome	2	accepted	EID1940 In a study of 468 colorectal adenocarcinoma 61 patients had micro-satellite instability (MSI) and there was a marginally statistically significantly better prognosis for BRAF WT (n=26) patients relati… (full text at CIViC) PMID 27302369 · Schell et al., 2016 · Open in CIViC	civic
NOT KRAS Mutation AND ( BRAF V600E OR BRAF D594G )	Cetuximab + ChemotherapyCombination	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID11060 The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC	civic

Conjunctival Melanoma1
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	2	submitted	EID3790 In a conjunctival malignant melanoma patient harboring a BRAF V600E mutation, BRAF V600E was associated with response to vemurafenib treatment. Prior to identification of the BRAF V600E mutation, the … (full text at CIViC) PMID 27520988 · Maleka et al., 2016 · Open in CIViC	civic

Cutaneous Melanoma3
BRAF V600E	Dabrafenib	Predictive	B	Supports Sensitivity Response	—	submitted	EID2146 In a phase 2 clinical trial with 250 metastatic melanoma BRAF-V600E patients, treatment groups were randomly assigned to either dabrafenib, BRAF specific inhibitor, (n=187) or dacarbazine, a standard… (full text at CIViC) PMID 22735384 · Hauschild et al., 2012 · Open in CIViC	civic
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	B	Supports Sensitivity Response	4	accepted	EID3758 In a clinical trial (NCT01597908) of 704 metastatic melanoma patients, patients harboring a BRAF V600E mutation and treated with vemurafenib (n=317) were associated with a 51% response rate, as compar… (full text at CIViC) PMID 25399551 · Robert et al., 2015 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	A	Supports Sensitivity Response	5	accepted	EID1409 Phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. At 6 months, overall survival was … (full text at CIViC) PMID 21639808 · Chapman et al., 2011 · Open in CIViC	civic

Diffuse Large B-Cell Lymphoma1
BRAF V600E	Venetoclax	Predictive	D	Supports Resistance	3	submitted	EID8952 In a preclinical study, Diffuse large B-cell lymphoma cell lines expressing BRAF V600E were resistant to a BCL-2 inhibitor, venetoclax, demonstrating cell growth inhibition at half-maximal growth inhi… (full text at CIViC) PMID 29463802 · Herling et al., 2018 · Open in CIViC	civic

Digestive System Neuroendocrine Tumor1
BRAF V600E	Dabrafenib + Trametinib + VemurafenibCombination	Predictive	C	Supports Sensitivity Response	3	accepted	EID1430 BRAF mutations were identified in 9% of 108 cases of high-grade colorectal neuroendocrine tumors (80% V600E). Two patients were treated with a combination of BRAF and MEK inhibition and exhibited dura… (full text at CIViC) PMID 27048246 · Klempner et al., 2016 · Open in CIViC	civic

Ganglioglioma3
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3778 A grade I refractory brainstem ganglioglioma patient harboring BRAF V600E mutation was associated with partial response to vemurafenib monotherapy. The patient experienced significant clinical improve… (full text at CIViC) PMID 26579623 · Aguilera et al., 2016 · Open in CIViC	civic
BRAF V600E	Cobimetinib + VemurafenibCombination	Predictive	C	Supports Sensitivity Response	1	submitted	EID11310 In this case study, a 32-year-old man, previously fit and well, presented with a two-month history of vertigo, right visual disturbance, dysphagia, and ataxia. Brain MRI revealed a large mixed solid a… (full text at CIViC) PMID 31985841 · Yau et al., 2020 · Open in CIViC	civic
BRAF V600E AND CDKN2A Deletion AND CDKN2B Deletion AND TET2 E796K AND BAX L76R AND AXIN2 P455K	Cobimetinib + VemurafenibCombination	Predictive	C	Supports Sensitivity Response	1	submitted	EID11314 In this case study, a 28-year-old male with BRAF V600E-mutant anaplastic ganglioglioma was started with vemurafenib at 960 mg twice daily in March 2015 for tumour recurrence despite one surgical resec… (full text at CIViC) PMID 30120137 · Touat et al., 2018 · Open in CIViC	civic

Glioblastoma1
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3771 In a case study, a pediatric grade IV glioblastoma multiforme patient harboring BRAF V600E mutation was associated with a complete response to vemurafenib monotherapy after 4 months of treatment, whic… (full text at CIViC) PMID 24725538 · Robinson et al., 2014 · Open in CIViC	civic

Hairy Cell Leukemia8
BRAF V600E	(diagnostic)	Diagnostic	B	Supports Positive	4	accepted	EID1127 In 47 patients with Hairy Cell Leukemia, sequencing discovered a V600E mutation in all 47 of the sequenced patients. PMID 21663470 · Tiacci et al., 2011 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	B	Supports Sensitivity Response	2	accepted	EID1579 Two clinical trials evaluated the effects of vemurafenib in 54 patients with BRAF (V600E) positive hairy-cell leukemia. The overall response rate was 98% with 19/54 having a complete response and 34/… (full text at CIViC) PMID 26352686 · Tiacci et al., 2015 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	B	Supports Sensitivity Response	3	submitted	EID11315 In these two phase II studies (Italy and U.S. locations), BRAF V600E-mutant hairy-cell leukemia was treated with vemurafenib at a dose of 960 mg twice daily to investigate its efficacy. The overall re… (full text at CIViC) PMID 26352686 · Tiacci et al., 2015 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3766 In a refractory hairy cell leukemia patient harboring BRAF V600E mutation, BRAF V600E was associated with sensitivity to vemurafenib treatment. The patient was initially treated with conventional trea… (full text at CIViC) PMID 22621641 · Dietrich et al., 2012 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3767 In a case report, a hairy cell leukemia (HCL) patient harboring BRAF V600E mutation was associated with a complete response to vemurafenib monotherapy after 3 months of treatment, which was sustained … (full text at CIViC) PMID 23300174 · Peyrade et al., 2013 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3768 In a hairy cell leukemia patient harboring BRAF V600E mutation, BRAF V600E mutation was associated with improved response to vemurafenib treatment. The patient was treated with 3 lines of chemotherapy… (full text at CIViC) PMID 23278307 · Follows et al., 2013 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3769 As a follow-up to a previous study (23300174), a hairy cell leukemia patient harboring BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was previously treated w… (full text at CIViC) PMID 25815361 · Bailleux et al., 2015 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3770 A hairy cell leukemia patient with extensive CNS involvement patient harboring BRAF V600E mutation was associated with complete response to vemurafenib monotherapy. Upon identification of the BRAF V60… (full text at CIViC) PMID 27116997 · McDowell et al., 2016 · Open in CIViC	civic

High-Grade Glioma, NOS7
BRAF V600E	Selumetinib	Predictive	B	Supports Sensitivity Response	—	submitted	EID2145 In a study of pediatric low-grade gliomas, BRAF V600E mutation was associated with a strong trend toward reduced progression free survival (HR:2.39, 95%CI:0.93-6.15, P=0.07, multivariate analysis). PMID 22492957 · Horbinski et al., 2012 · Open in CIViC	civic
BRAF V600E	Selumetinib	Predictive	D	Supports Sensitivity Response	—	submitted	EID2144 In a mouse xenograft model, tumors derived from pilocytic astrocytoma cells that expressed BRAF V600E experienced a complete response to treatment with selumetinib, whereas tumors derived from a wildt… (full text at CIViC) PMID 20806365 · Kolb et al., 2010 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	B	Supports Sensitivity Response	—	rejected	EID3763 A study of pediatric malignant astrocytomas found that tumors with BRAF V600E mutations also had homozygous deletions of CDKN2A more frequently than those with wildtype BRAF (71% vs. 8% , P=0.0016, F… (full text at CIViC) PMID 20068183 · Schiffman et al., 2010 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	B	Supports Sensitivity Response	—	rejected	EID3764 In a study of pilocytic astrocytomas, presence of the BRAF V600E mutation was more frequently detected in extra-cerebellar pilocytic astrocytomas than cerebellar ones (20% vs. 2% , P=0.009, Fisher�s… (full text at CIViC) PMID 21274720 · Schindler et al., 2011 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	B	Supports Sensitivity Response	—	rejected	EID3765 In a study of low grade pediatric gliomas, 19 of 157 tumors had a BRAF V600E mutation. Tumors located in the cerebrum had a higher frequency of BRAF mutations than those in the cerebellum or midline (… (full text at CIViC) PMID 22492957 · Horbinski et al., 2012 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	2	submitted	EID12719 In an open-label phase II Pediatric MATCH subprotocol of vemurafenib for relapsed or refractory solid tumors with BRAF V600 mutations (NCT03220035; n = 4 evaluable), all four treated patients carried … (full text at CIViC) PMID 38873934 · Nelson et al., 2024 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	D	Supports Sensitivity Response	—	submitted	EID3762 In a mouse xenograft model, tumors derived from the glioblastoma cell line AM-38 that were treated with vemurafenib had reduced tumor growth and improved survival compared to control treated mice (P=0… (full text at CIViC) PMID 22038996 · Nicolaides et al., 2011 · Open in CIViC	civic

Histiocytoma1
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3789 A primary central nervous system (CNS)-histiocytic sarcoma patient harboring BRAF V600E mutation was associated with improved response to vemurafenib treatment. The patient was treated with vemurafeni… (full text at CIViC) PMID 25209580 · Idbaih et al., 2014 · Open in CIViC	civic

Intrahepatic Cholangiocarcinoma2
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	C	Supports Sensitivity Response	3	accepted	EID5903 Two cases of patients with BRAF V600E positive, refractory intrahepatic cholangiocarcinoma showed excellent clinical and radiographic response to combination dabrafenib and trametinib treatment. One p… (full text at CIViC) PMID 28078132 · Lavingia et al., 2016 · Open in CIViC	civic
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	C	Supports Sensitivity Response	3	accepted	EID5904 Dabrafenib and trametinib combination showed durable response for a patient with standard chemotherapy and radiation refractory, poorly differentiated, intrahepatic cholangiocarcinoma harboring BRAF V… (full text at CIViC) PMID 25435907 · Loaiza-Bonilla et al., 2014 · Open in CIViC	civic

Langerhans Cell Histiocytosis1
BRAF V600E	Dabrafenib	Predictive	B	Supports Sensitivity Response	4	submitted	EID11303 In this case series, 11 patients with ECD or ECD/LCH (Seven had ECD and four had overlapped ECD/LCH) were treated with single-agent dabrafenib as initial histiocytosis therapy, following the failure o… (full text at CIViC) PMID 29472347 · Bhatia et al., 2018 · Open in CIViC	civic

Langerhans Cell Sarcoma1
BRAF V600E	Vemurafenib	Predictive	B	Supports Sensitivity Response	4	accepted	EID7583 Off-label use of vemurafenib to treat BRAF V600E mutation-positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated. Fifty-four patients from 12 countries were treated with vem… (full text at CIViC) PMID 31513482 · Donadieu et al., 2019 · Open in CIViC	civic

Laryngeal Squamous Cell Carcinoma1
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	3	accepted	EID5962 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient … (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic

Low Grade Glioma2
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	A	Supports Sensitivity Response	4	accepted	EID12162 In this trial, patients with pediatric (age <18 years) low-grade gliomas harbouring BRAF V600E (n=49), were treated with either trametinib monotherapy (n=13) or dabrafenib + trametinib (n=36). In pati… (full text at CIViC) PMID 36375115 · Bouffet et al., 2023 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	B	Supports Sensitivity Response	3	accepted	EID11770 In this trial, 19 patients with pediatric brain tumours (1 patient with Astrocytoma, 1 with Fibrillary Astrocytoma, 10 with Pilocytic Astrocytoma, 5 with Ganglioglioma and 2 with Pleomorphic Xanthoast… (full text at CIViC) PMID 32523649 · Nicolaides et al., 2020 · Open in CIViC	civic

Lung Adenocarcinoma5
BRAF V600E	Vemurafenib	Predictive	B	Supports Sensitivity Response	—	submitted	EID3782 In a retrospective study of 35 lung adenocarcinoma patients (with chemotherapy previously administered in 86% of patients), patients harboring a BRAF V600E mutation and treated with vemurafenib monoth… (full text at CIViC) PMID 26200454 · Gautschi et al., 2015 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3780 In a lung adenocarcinoma patient with brain metastases harboring BRAF V600E mutation, BRAF V600E was associated with sensitivity to vemurafenib treatment. Upon treatment with vemurafenib monotherapy, … (full text at CIViC) PMID 24888229 · Robinson et al., 2014 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3781 In a stage IV non-small cell lung cancer patient with a BRAF V600E mutation, who developed adenocarcinoma, BRAF V600E was associated with sensitivity to vemurafenib treatment. The patient was initiall… (full text at CIViC) PMID 23733758 · Peters et al., 2013 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3783 A stage IV lung adenocarcinoma patient harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient�s prior treatment regimens were complex, including radiother… (full text at CIViC) PMID 26776917 · Myall et al., 2016 · Open in CIViC	civic
BRAF V600E AND EGFR L858R AND EGFR T790M	Osimertinib	Predictive	C	Supports Resistance	3	submitted	EID11098 A 42 year old man with non-smoking history presented with EGFR L858R positive lung adenocarcinoma. He was given various treatments including erlotinib and gefitinib and progressed four years later. bi… (full text at CIViC) PMID 29074209 · Bearz et al., 2017 · Open in CIViC	civic